CA2186873A1 - Peptides haptines et leurs utilisations - Google Patents

Peptides haptines et leurs utilisations

Info

Publication number
CA2186873A1
CA2186873A1 CA 2186873 CA2186873A CA2186873A1 CA 2186873 A1 CA2186873 A1 CA 2186873A1 CA 2186873 CA2186873 CA 2186873 CA 2186873 A CA2186873 A CA 2186873A CA 2186873 A1 CA2186873 A1 CA 2186873A1
Authority
CA
Canada
Prior art keywords
seq
peptide
ala
pdc
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2186873
Other languages
English (en)
Inventor
Charles J. Hackett
Julia L. Greenstein
Malcolm L. Gefter
Kurt Jeff Wilson
Cohava Gelber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Immulogic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corp filed Critical Immulogic Pharmaceutical Corp
Publication of CA2186873A1 publication Critical patent/CA2186873A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des peptides transporteurs se liant à l'antigène MHC, ces peptides présentant des liaisons avec des dérivés de la catéchine et étant reconnus par les lymphocytes T spécifiques de l'urushiol. Les composés sont utilisables pour les compositions et procédés thérapeutiques de désensibilisation des individus contre les sensibilisations par contacts avec l'haptine, tels que le sumac vénéneux ou le chêne vénéneux.
CA 2186873 1994-04-01 1995-03-30 Peptides haptines et leurs utilisations Abandoned CA2186873A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22220694A 1994-04-01 1994-04-01
US08/222,206 1994-04-01
US38364595A 1995-02-06 1995-02-06
US08/383,645 1995-02-06

Publications (1)

Publication Number Publication Date
CA2186873A1 true CA2186873A1 (fr) 1995-10-12

Family

ID=26916551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2186873 Abandoned CA2186873A1 (fr) 1994-04-01 1995-03-30 Peptides haptines et leurs utilisations

Country Status (3)

Country Link
AU (1) AU2238395A (fr)
CA (1) CA2186873A1 (fr)
WO (1) WO1995026980A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
ATE296444T1 (de) 1996-03-21 2005-06-15 Circassia Ltd Kryptische peptide und verfahren zu ihrer identifizierung
CA2252417A1 (fr) * 1996-06-07 1997-12-11 Zeneca Limited Derives de peptides
EP0960119B1 (fr) * 1996-06-11 2008-09-17 Northern Sydney and Central Coast Area Health Service Peptides recepteurs d'antigene des cellules t
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
WO1999034826A1 (fr) * 1998-01-09 1999-07-15 Circassia Limited Procedes et compositions de desensibilisation
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (fr) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
CA2337688C (fr) 1998-07-23 2016-04-05 Yeda Research And Development Co., Ltd. Traitement de maladies auto-immunes a l'aide du copolymere 1 et copolymeres associes
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
EP1128839A4 (fr) * 1998-11-12 2002-10-09 Yeda Res & Dev Compositions pharmaceutiques comprenant des copolymeres de peptides synthetiques et methodes de prevention et de traitement de la reaction du greffon contre l'hote (gvhd) et de la reaction de l'hote contre le greffon (hvgd)
US7053043B1 (en) 1999-07-23 2006-05-30 Yeda Research And Development Co.Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
WO2003048735A2 (fr) 2001-12-04 2003-06-12 Teva Pharmaceutical Industries, Ltd. Procedes pour mesurer la puissance de l'acetate de glatiramer
ATE414534T1 (de) * 2001-12-05 2008-12-15 Circassia Ltd Immunotherapeutische methoden und systeme
GB2440529B (en) * 2006-08-03 2009-05-13 Proimmune Ltd MHC Oligomer, Components Therof, And Methods Of Making The Same
CN110801013B (zh) * 2019-11-19 2023-03-31 西北农林科技大学 一种生物化学法制备非过敏生漆或漆酚的方法及其产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428965A (en) * 1979-05-31 1984-01-31 The University Of Mississippi Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae families
EP0555418A4 (en) * 1990-10-30 1994-06-01 Immulogic Pharma Corp Peptide binding assays with mhc antigens
WO1992011859A1 (fr) * 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Hyposensibilisation induite par un peptide de la reponse des lymphocytes t humains a des dermatophagoides (dermatophagoides pteronyssimus)

Also Published As

Publication number Publication date
AU2238395A (en) 1995-10-23
WO1995026980A2 (fr) 1995-10-12
WO1995026980A3 (fr) 1995-12-07

Similar Documents

Publication Publication Date Title
CA2186873A1 (fr) Peptides haptines et leurs utilisations
Moyle et al. Self-adjuvanting lipopeptide vaccines
US6610659B1 (en) Use of heat shock protein 70 preparations in vaccination against cancer and infectious disease
CA2167730A1 (fr) Peptides synthetiques de type mucine et analogues, renfermant des sequences repetees et multiples d'acides amines; leur utilisation
JP7102430B2 (ja) 糖尿病の治療のためのペプチド及び方法
HU229489B1 (hu) Tolerogén peptidek
JP2001527029A (ja) 抗レトロウイルス免疫原、調製および使用
CA2715484A1 (fr) Suppression des reponses immunitaires aux vecteurs viraux
AU679439B2 (en) Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens
US20030175285A1 (en) Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
BR112021009210A2 (pt) peptídeos imunogênicos com motivos de oxidorredutase melhorados
CA2508539A1 (fr) Antigenes specifiques gp120, leurs conjugues, leur procedes de preparation et leur utilisation
Curicio‐Vonlanthen et al. Molecular parameters in melittin immunogenicity
EP3969039A1 (fr) Peptides immunogènes avec un motif oxydoréductase comprenant une cystéine modifiée
Brander et al. Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL)
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
WO2003061589A2 (fr) Methodes permettant de traiter des maladies ou des troubles a l'aide de constructions peptidiques
JP2005527513A (ja) ワクチン製造のためのリポペプチド混合物の使用
US20200188511A1 (en) Methods of improving efficacy of allergy vaccines
FR2842812A1 (fr) Procede de solubilisation de peptides hydrophobes et leur utilisation pour generer une reponse de type ctl antitumorale ou anti-infectueuse

Legal Events

Date Code Title Description
FZDE Dead